GLP1R and metabolic dysfunction-associated steatohepatitis: Currently, pipeline drugs such as aramchol, GLP-1 receptor agonists, and cenicriviroc as well as OCA have all shown efficacy in improving NASH liver histology in NASH patients (Safadi et al., 2014; Armstrong et al., 2016; Friedman et al., 2018b; Eslam et al., 2019).